Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (14416)
All Articles published online
|
Publishing Process of This Article
|
Mar 9, 2016 (publication date) through Feb 2, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Pharmacology
ISSN
2220-3192
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Pelletier AL, Nicaise-Roland P. Adalimumab and pharmacokinetics: Impact on the clinical prescription for inflammatory bowel disease. World J Pharmacol 2016; 5(1): 44-50 [DOI: 10.5497/wjp.v5.i1.44] |
|---|---|
| URL: | https://www.wjgnet.com/2220-3192/full/v5/i1/44.htm |
| Number | Citing Articles |
| 1 |
Cátia Rocha, Joana Afonso, Paula Lago, Bruno Arroja, Ana I. Vieira, Claudia C. Dias, Fernando Magro. Accuracy of the new rapid test for monitoring adalimumab levels. Therapeutic Advances in Gastroenterology 2019; 12 doi: 10.1177/1756284819828238
|
| 2 |
Neeraj Narula, Brian Lauzon, John K. Marshall. Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2019; 54(6): 712 doi: 10.1080/00365521.2019.1621367
|